CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

INmune Bio targets Ebstrocel U.K. MAA by end of Q3 or early Q4 2026 while outlining $1M-$1.5M monthly burn

RegulatoryEbstrocelNeutral
AI Analysis

Summary

INmune Bio targets a U.K. MAA filing for Ebstrocel by end of Q3 or early Q4 2026, with monthly cash burn guidance of $1M-$1.5M.

Importance:5/10
Sentiment:
0.00
regulatoryMAAcash_burnUK
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on August 7, 2026 12:05 PM

Read Original